77937687 - ARK THERAPEUTICS

Information

• Trademark
• 77937687

• Source

• Serial Number

  77937687

• Registration Number

  4184675

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 10 - Surgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teeth
  • 42 - Scientific and technological services and research and design relating thereto

• Filing Date

  February 17, 2010
  14 years ago

• Registration Date

  August 07, 2012
  12 years ago

• Transaction Date

  April 16, 2019
  5 years ago

• Status Date

  March 08, 2019
  5 years ago

• Published for Opposition Date

  April 03, 2012
  12 years ago

• Location Date

  August 07, 2012
  12 years ago

• Status Code

  710

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  LE, KHANH M

• Attorney Docket Number

  S14453

  Attorney Name

  Leigh Ann Lindquist

  Law Office Assigned Location Code

  M40

• Owners

  • Ark Therapeutics Limited

Case File Statements

• CC0000: Color is not claimed as a feature of the mark.
• D10000: "THERAPEUTICS"
• GS0011: Diagnostic protein preparations for use in science, scientific diagnostics, medical laboratory use and research; diagnostic preparations of genes for use in science, scientific diagnostics, medical laboratory use and research
• GS0051: Diagnostic protein preparations for medical use; diagnostic preparations of genes for medical use; pharmaceutical preparations for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; pharmaceutical preparations for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; pharmaceutical preparations to promote or suppress angiogenesis and enhance blood flow; pharmaceutical preparations for increasing the efficiency of muscle cell energy production; therapeutic agents for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; therapeutic agents for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; therapeutic agents to promote or suppress angiogenesis and enhance blood flow; therapeutic agents for increasing the efficiency of muscle cell energy production; diagnostic preparations for medical purposes; protein preparations for clinical or medical laboratory use, namely, for targeting therapeutic agents to specific sites; medical dressings; surgical dressings; burn dressings; wound dressings; absorbent wound and burn dressings in the nature of pads; foot and hand dressings for medical purposes; fluid handling foot and hand dressings for medical purposes; preparations of genes for therapeutic purposes, namely, for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; preparations of genes for therapeutic purposes, namely, for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; preparations of genes for therapeutic purposes, namely, to promote or suppress angiogenesis and enhance blood flow; preparations of genes for therapeutic purposes, namely, for increasing the efficiency of muscle cell energy production; foot and hand dressings for medical purposes, namely, for the treatment of wounds and burns; none of the above including dietary and nutritional supplements
• GS0101: Boots and gloves for orthopaedic and medical purposes; parts of boots and gloves for orthopedic and medical purposes, namely, heels, soles and inserts; boots and gloves for medical purposes with the ability to handle wound fluid; boots and gloves for medical use and absorbent filters, liners and inserts for use therewith; filters, soles and absorbent inserts for boots and gloves for medical purposes, namely, for the treatment of wounds and burns; biodegradable collagen collar delivery devices for delivering therapeutic agents and gene therapy products to specific sites
• GS0421: Scientific, medical and clinical research, all in the field of the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting, prevention of stenosis, increasing the efficiency of muscle cell energy production and promoting or suppressing angiogenesis and enhancing blood flow; providing scientific, medical and clinical research information, all in the field of the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting, prevention of stenosis, increasing the efficiency of muscle cell energy production and promoting or suppressing angiogenesis and enhancing blood flow; scientific, medical and clinical research for the discovery, design, creation, development and testing in the field of pharmaceutical preparations and therapeutically active substances; scientific, medical and clinical research in the field of gene therapy; scientific, medical and clinical research for the discovery, design, creation, development and testing in the field of pharmaceutical preparations and therapeutically active substances for use in the field of gene therapy; scientific, medical and clinical research in the field of genes and genetics; medical and scientific research, namely, conducting gene therapy trials; none of the above in the dietary or nutritional supplement field

Case File Event Statements

• 3/8/2019 - 5 years ago

  41 - CANCELLED SEC. 8 (6-YR) Type: C8..

• 8/7/2017 - 7 years ago

  40 - COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Type: REM1

• 8/7/2012 - 12 years ago

  39 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 6/28/2012 - 12 years ago

  38 - 1(B) BASIS DELETED; PROCEED TO REGISTRATION Type: DP1B

• 6/28/2012 - 12 years ago

  37 - NOTICE OF ALLOWANCE CANCELLED Type: IUCN

• 6/28/2012 - 12 years ago

  36 - CASE ASSIGNED TO INTENT TO USE PARALEGAL Type: AITU

• 6/22/2012 - 12 years ago

  35 - TEAS DELETE 1(B) BASIS RECEIVED Type: D1BR

• 5/29/2012 - 12 years ago

  34 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM

• 4/3/2012 - 12 years ago

  33 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 4/3/2012 - 12 years ago

  32 - PUBLISHED FOR OPPOSITION Type: PUBO

• 3/14/2012 - 12 years ago

  31 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 2/27/2012 - 12 years ago

  30 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV

• 2/21/2012 - 12 years ago

  29 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 2/10/2012 - 12 years ago

  28 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 2/10/2012 - 12 years ago

  27 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 2/10/2012 - 12 years ago

  26 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 2/10/2012 - 12 years ago

  25 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 2/1/2012 - 12 years ago

  24 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 2/1/2012 - 12 years ago

  23 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 1/10/2012 - 12 years ago

  22 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 7/12/2011 - 13 years ago

  21 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 7/12/2011 - 13 years ago

  20 - NON-FINAL ACTION E-MAILED Type: GNRT

• 7/12/2011 - 13 years ago

  19 - NON-FINAL ACTION WRITTEN Type: CNRT

• 6/21/2011 - 13 years ago

  18 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 6/21/2011 - 13 years ago

  17 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 6/15/2011 - 13 years ago

  16 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 12/21/2010 - 13 years ago

  15 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 12/21/2010 - 13 years ago

  14 - NON-FINAL ACTION E-MAILED Type: GNRT

• 12/21/2010 - 13 years ago

  13 - NON-FINAL ACTION WRITTEN Type: CNRT

• 11/30/2010 - 13 years ago

  12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 11/30/2010 - 13 years ago

  11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 11/29/2010 - 13 years ago

  10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 5/27/2010 - 14 years ago

  9 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 5/27/2010 - 14 years ago

  8 - NON-FINAL ACTION E-MAILED Type: GNRT

• 5/27/2010 - 14 years ago

  7 - NON-FINAL ACTION WRITTEN Type: CNRT

• 5/20/2010 - 14 years ago

  6 - ASSIGNED TO EXAMINER Type: DOCK

• 4/9/2010 - 14 years ago

  5 - APPLICANT AMENDMENT PRIOR TO EXAMINATION - ENTERED Type: AMPX

• 4/8/2010 - 14 years ago

  4 - ASSIGNED TO LIE Type: ALIE

• 3/29/2010 - 14 years ago

  3 - TEAS VOLUNTARY AMENDMENT RECEIVED Type: PARI

• 2/23/2010 - 14 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS

• 2/20/2010 - 14 years ago

  1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP